about
Neuroimaging of the periaqueductal gray: state of the fieldA systematic review of physiological methods in rodent pharmacological MRI studies.Serotonin transporter availability in the amygdala and bed nucleus of the stria terminalis predicts anxious temperament and brain glucose metabolic activityUsing NMR approaches to drive the search for new CNS therapeutics.Healthy individuals treated with clomipramine: an fMRI study of brain activity during autobiographical recall of emotions.Pharmacologic magnetic resonance imaging (phMRI): imaging drug action in the brain.Systemic inflammation alters central 5-HT function as determined by pharmacological MRIAffective cognition and its disruption in mood disorders.Escitalopram Decreases Cross-Regional Functional Connectivity within the Default-Mode Network.Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).The effects of Psychotropic drugs On Developing brain (ePOD) study: methods and designBrain serotonergic circuitriesInverse fluoxetine effects on inhibitory brain activation in non-comorbid boys with ADHD and with ASD.Effects of oxytocin and vasopressin on the neural response to unreciprocated cooperation within brain regions involved in stress and anxiety in men and womenSelective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI studyAcute effects of Sceletium tortuosum (Zembrin), a dual 5-HT reuptake and PDE4 inhibitor, in the human amygdala and its connection to the hypothalamus.Differential Effects of Single-Dose Escitalopram on Cognitive and Affective Interference during Stroop Task.The use of pharmacological-challenge fMRI in pre-clinical research: application to the 5-HT system.Imaging genetics: implications for research on variable antidepressant drug response.
P2860
Q24289416-8A358DD5-36A1-4D67-B1B8-F54E805D8E17Q30420324-7149F3A2-22DD-475D-B904-E80E476D73A7Q30490740-9E96518A-1B9A-461C-963C-BA60DA0B3EE5Q33613767-2DDB6DB3-661C-422A-BC23-5B0CDD762812Q33840518-7D6575C5-C0C8-41AF-AB28-489AE72333D6Q34229087-99D61B36-4EE7-403E-B721-553D71213BDAQ34615371-6651926A-7A3A-4A02-9847-BD1C39044677Q34661207-A4EC7E5A-1F84-4494-9CDB-40ACD6FD153DQ34797989-F8289652-B156-4122-A85C-EAD67EE70914Q34893388-9FC7FFC0-B2BD-4956-BDFA-A98F6131B477Q35098070-19D32722-363A-46C1-9485-94DEF56791D7Q35237299-8FA3D0DF-FAB0-47F1-AC3E-972582D5F6BDQ35607540-07746168-6DD5-40F3-846C-9D220F78FD42Q36348375-0908E845-5B6F-4F06-B89F-E28D9806C097Q36925361-B2979E40-B012-4B53-8876-673B1CCF07FAQ37309777-FFC31FD0-C62A-483B-813A-5CB8080FA687Q41977122-3417C2AA-786A-4235-B6E5-337B80CD6770Q42169859-73934B5C-6787-4F3C-8276-5824BB031184Q48148747-FF37FFB6-E57C-4FAF-8BD5-C5F7EDAECA2C
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Assessing human 5-HT function in vivo with pharmacoMRI.
@ast
Assessing human 5-HT function in vivo with pharmacoMRI.
@en
type
label
Assessing human 5-HT function in vivo with pharmacoMRI.
@ast
Assessing human 5-HT function in vivo with pharmacoMRI.
@en
prefLabel
Assessing human 5-HT function in vivo with pharmacoMRI.
@ast
Assessing human 5-HT function in vivo with pharmacoMRI.
@en
P2093
P1433
P1476
Assessing human 5-HT function in vivo with pharmacoMRI.
@en
P2093
I M Anderson
S R Williams
P304
P356
10.1016/J.NEUROPHARM.2008.06.029
P577
2008-06-25T00:00:00Z